340B Partnership Expansion Red Chip already serves Hemophilia Treatment Centers and manages 340B outpatient factor programs along with billing and collections for high-cost meds. This positions the company as a broker between HTCs, manufacturers, and payers, creating a strong channel for expanded 340B services. Sales opportunity: offer enhanced 340B program optimization, audit support, and partnerships with manufacturers and distributors to improve discount capture and invoicing efficiency.

Nationwide Distribution Reach With pharmacy licenses across many states and involvement in limited-distribution models for high-cost drugs, Red Chip can be a valuable partner for manufacturers and specialty distributors seeking compliant, multi-state distribution for small chronically ill populations. Potential play: offer end-to-end distribution support, licensure facilitation, and compliance analytics to scale limited-distribution programs.

Revenue Cycle Focus The company's reputation for superior billing and collection services for high-cost meds suggests opportunities to extend specialized revenue cycle management to additional HTCs or clinics. Sales angles: provide RCM modernization, denial management, patient financial counseling, and data analytics to maximize reimbursements and reduce bad debt in 340B workflows.

Security and Compliance The tech stack includes security and privacy tools, signaling a priority on secure data handling. This creates openings to offer HIPAA-compliant data integration, secure 340B program reporting, and audit-ready architecture for HTCs, manufacturers, and payers.

Growth-Oriented MSP A lean team and mid-market revenue profile indicate Red Chip could scale through partnerships with MSPs, clinical operations consultants, or software vendors to broaden 340B program administration, vendor enrollment, and inventory/factor program analytics for HTCs and pharma partners.